Simulations Plus to Present at LD Micro 11th Annual Main Event Investor Conference on December 4, 2018

Simulations Plus, Inc. SLP, a leading provider of software for pharmaceutical discovery and development, today announced that Shawn O'Connor, chief executive officer, and John Kneisel, chief financial officer, will present at the 11th Annual LD Micro Main Event investor conference at 9 a.m. PT on Tuesday, December 4, 2018, at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The conference will be held December 4-6, 2018.

In addition, management will be available during the day on Tuesday and Wednesday, December 4 and 5, for one-on-one meetings. For more information about the conference or to schedule a one-on-one meeting with management, please contact Hayden IR at slp@haydenir.com. Following the presentation, the slides will be available via the Resource Center at the Simulations Plus website (www.simulations-plus.com).

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit and Main Event). In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure micro-cap index (LDMi), which covers stocks in North America with market capitalizations between $50 million to $300 million.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005210/en/